[go: up one dir, main page]

MX9500072A - Compuestos con propiedades de liberacion de la hormona del crecimiento. - Google Patents

Compuestos con propiedades de liberacion de la hormona del crecimiento.

Info

Publication number
MX9500072A
MX9500072A MX9500072A MX9500072A MX9500072A MX 9500072 A MX9500072 A MX 9500072A MX 9500072 A MX9500072 A MX 9500072A MX 9500072 A MX9500072 A MX 9500072A MX 9500072 A MX9500072 A MX 9500072A
Authority
MX
Mexico
Prior art keywords
compounds
growth hormone
hormone releasing
releasing properties
properties
Prior art date
Application number
MX9500072A
Other languages
English (en)
Inventor
Niels Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Henning Thogersen
Birgit Sehested Hansen
Bernd Peschke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143993A external-priority patent/DK143993D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX9500072A publication Critical patent/MX9500072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos de la formula A-B-C-D(-E)p se utilizan para estimular la liberacion de hormona del crecimiento desde la pituitaria.
MX9500072A 1993-12-23 1995-01-02 Compuestos con propiedades de liberacion de la hormona del crecimiento. MX9500072A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK143993A DK143993D0 (es) 1993-12-23 1993-12-23
DK12194 1994-01-28
DK119194 1994-10-14

Publications (1)

Publication Number Publication Date
MX9500072A true MX9500072A (es) 1997-05-31

Family

ID=27220421

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9500072A MX9500072A (es) 1993-12-23 1995-01-02 Compuestos con propiedades de liberacion de la hormona del crecimiento.

Country Status (27)

Country Link
US (1) US5767085A (es)
EP (1) EP0736039B1 (es)
JP (1) JP3181918B2 (es)
KR (1) KR100354897B1 (es)
CN (1) CN1052731C (es)
AT (1) ATE197158T1 (es)
AU (1) AU689181B2 (es)
BR (1) BR9408377A (es)
CA (1) CA2179597A1 (es)
CZ (1) CZ293113B6 (es)
DE (1) DE69426206T2 (es)
DK (1) DK0736039T3 (es)
ES (1) ES2153469T3 (es)
FI (1) FI962584A0 (es)
GR (1) GR3035150T3 (es)
HU (1) HU224345B1 (es)
IL (1) IL112112A (es)
MX (1) MX9500072A (es)
NO (1) NO315561B1 (es)
NZ (1) NZ277486A (es)
PL (1) PL181280B1 (es)
PT (1) PT736039E (es)
RO (1) RO115635B1 (es)
SG (1) SG55069A1 (es)
SK (1) SK281963B6 (es)
UA (1) UA42747C2 (es)
WO (1) WO1995017423A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176140A1 (en) * 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
DE69427650T2 (de) * 1993-12-23 2001-11-22 Novo Nordisk A/S, Bagsvaerd Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
AU705744B2 (en) 1995-01-27 1999-06-03 Sapphire Therapeutics, Inc. Compounds with growth hormone releasing properties
HUP9802821A3 (en) * 1995-06-22 2000-03-28 Novo Nordisk As Compounds with growth hormone releasing properties
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
JP3798024B2 (ja) 1995-12-13 2006-07-19 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進物質レセプターアッセイ
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
EP0869974B1 (en) * 1995-12-22 2009-03-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
KR20000010626A (ko) * 1996-04-24 2000-02-25 한센 핀 베네드, 안네 제헤르 성장호르몬 방출성을 갖는 화합물
US5919777A (en) * 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
JP4425992B2 (ja) * 1996-07-22 2010-03-03 サファイア セラピューティクス，インコーポレイティド 成長ホルモン放出特性を有する化合物
AU3938797A (en) * 1996-08-29 1998-03-19 Novo Nordisk A/S Transdermal delivery of peptides
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
KR20010034198A (ko) 1998-01-16 2001-04-25 한센 핀 베네드 성장 호르몬 방출성을 가지는 화합물
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
JP2002520011A (ja) 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド 成長ホルモン分泌促進物質関連受容体および核酸
WO2000009538A2 (en) 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
CA2356109C (en) 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
KR100699404B1 (ko) * 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
EP1200111A1 (en) * 1999-06-04 2002-05-02 Novo Nordisk A/S Compositions for the treatment of the catabolic state of prolonged critical illness
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
MXPA05012505A (es) * 2003-05-19 2006-01-30 Warner Lambert Co Capsula de gelatina dura que contiene oxido de titanio con un tamano de particula controlado y procedimiento para su produccion.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
NZ545940A (en) 2003-09-12 2009-12-24 Tercica Inc Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005097261A1 (en) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR101380200B1 (ko) * 2004-08-12 2014-04-01 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을촉진하는 방법
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2021015A2 (en) * 2006-04-28 2009-02-11 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
CN101686966A (zh) * 2007-02-13 2010-03-31 赫尔辛医疗（美国）有限公司 使用生长激素促分泌素治疗细胞增生疾病的方法
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
MX2011013113A (es) * 2009-06-12 2012-02-21 Helsinn Therapeutics Us Inc Soluciones de inyeccion e infusion de diacetato de ipamorelin.
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US12012467B2 (en) 2017-03-28 2024-06-18 Regents Of The University Of Michigan Small molecule DCN1 inhibitors and therapeutic methods using the same
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
CN119930744B (zh) * 2025-01-20 2025-12-19 昆明理工大学 一种发酵马乳源小分子肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
JPS58501861A (ja) * 1981-12-28 1983-11-04 ベツクマン・インストルメンツ・インコ−ポレ−テツド 下垂体成長ホルモン放出活性を有する合成ペプチド
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
EP0663834A4 (en) * 1992-09-25 1996-01-24 Smithkline Beecham Corp GROWTH HORMONE RELEASING PEPTIDES.
CA2176140A1 (en) * 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)

Also Published As

Publication number Publication date
EP0736039B1 (en) 2000-10-25
NZ277486A (en) 1997-03-24
ATE197158T1 (de) 2000-11-15
HU9501947D0 (en) 1995-11-28
KR100354897B1 (ko) 2003-01-06
IL112112A0 (en) 1995-03-15
AU689181B2 (en) 1998-03-26
BR9408377A (pt) 1997-08-19
PT736039E (pt) 2001-04-30
CN1138335A (zh) 1996-12-18
PL315113A1 (en) 1996-10-14
FI962584L (fi) 1996-06-20
FI962584A7 (fi) 1996-06-20
CN1052731C (zh) 2000-05-24
DE69426206D1 (de) 2000-11-30
SK281963B6 (sk) 2001-09-11
FI962584A0 (fi) 1996-06-20
UA42747C2 (uk) 2001-11-15
HUT73497A (en) 1996-08-28
HU224345B1 (hu) 2005-08-29
DE69426206T2 (de) 2001-05-17
DK0736039T3 (da) 2001-02-12
RO115635B1 (ro) 2000-04-28
SK82096A3 (en) 1997-01-08
JPH09507217A (ja) 1997-07-22
EP0736039A1 (en) 1996-10-09
IL112112A (en) 2000-06-29
NO962665L (no) 1996-08-23
PL181280B1 (pl) 2001-07-31
CZ293113B6 (cs) 2004-02-18
US5767085A (en) 1998-06-16
GR3035150T3 (en) 2001-04-30
CZ183496A3 (en) 1997-02-12
SG55069A1 (en) 1998-12-21
ES2153469T3 (es) 2001-03-01
NO962665D0 (no) 1996-06-21
CA2179597A1 (en) 1995-06-29
AU1272495A (en) 1995-07-10
JP3181918B2 (ja) 2001-07-03
WO1995017423A1 (en) 1995-06-29
NO315561B1 (no) 2003-09-22

Similar Documents

Publication Publication Date Title
MX9500072A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
MX9709278A (es) Dipeptidos que promueven la liberacion de la hormona de crecimiento, composiciones que los contienen y uso de los mismos.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2111092T3 (es) Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES2147759T3 (es) Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
ES2175741T3 (es) Nuevos derivados del acido sulfinico, su procedimiento de preparacion y su utilizacion.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
MX9100341A (es) Compuestos de polipeptido que tiene actividad liberadora de hormona de crecimiento
MX9302757A (es) Nuevos pirazoles, proceso para su preparacion y composicion fungicida que los contiene.
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.
MX9300412A (es) Derivados de 1h-bencimidazol sustituidos con pirroloimidazolilo e imadazopiridinilo
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
ES2077867T3 (es) 3-carbamoil-4-hidroxicumarinas antihelminticas y anticoccidiales, procedimiento de uso y composiciones.
ES2060944T3 (es) Derivados de 2,5,6,7-tetranor-4,8-inter-m-fenileno de pgi2 (prostaglandina i2).
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
MX9710377A (es) Compuestos con propiedades de liberacion de la hormona de crecimiento.
AR021616A1 (es) Cicloheptenos sustituidos, procedimiento para su preparacion y uso de los mismos.
ES2004215A6 (es) Procedimiento para preparar quinazolinas tetraciclicas
ES2150034T3 (es) Empleo de las 2-aminotetralinas substituidas en 6,7 para la preparacion de composiciones farmaceuticas de utilidad para el tratamiento del choque septico, y composiciones farmaceuticas antipireticas y antiinflamatorias.